European Pharmaceutical Review
APRIL 25, 2024
Research on the global pharmaceutical parenteral packaging market by InsightAce Analytic Pvt. Main drivers for the market were reported to be rising popularity of generics together with blockbuster and other small-molecule drugs going off-patent globally. has predicted that the sector will value $18.85 billion by 2031. Catalent Inc.
European Pharmaceutical Review
MARCH 14, 2023
This is due to the regulatory requirements imposed on parallel imported medicinal products in various Member States, the fulfilment of which often requires repackaging. Repackaging a medicinal product… means that the trademark is reapplied by an entity other than the trademark proprietor.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
OCTOBER 10, 2023
The big blow to Sunovion, he said, was the loss of patent protection for Latuda, its best-selling schizophrenia drug, which led to competition from cheaper generic medicines. “The severance package that I received from Sunovion was very generous and will tide me over until December,” he said. Absolutely.”
European Pharmaceutical Review
FEBRUARY 2, 2023
The recent update to the EC Urban Waste Directive, part of the environment package ‘Towards Zero Pollution,’ 4 has a disproportionate producer responsibility principle that will incur considerable extra costs. This is likely to make some essential medicines and APIs economically unsustainable to manufacture.
The Checkup by Singlecare
SEPTEMBER 8, 2023
It is also available as a generic medicine called amphetamine- dextroamphetamine ER. The packaging can also be convenient as the tablets come in portable blister packs for those on the go. Adzenys XR shares similar common side effects as Adderall XR and is taken once a day.
pharmaphorum
MAY 27, 2022
Liam Johnstone has six years of toxicology experience working across regulators in the UK, developing expertise in medicine, consumer product and agrochemical safety whilst working at the MHRA, OPSS and HSE, respectively. As a Non-Clinical Assessor at MHRA he assessed non-clinical data packages for new and generic medicines.
pharmaphorum
JANUARY 30, 2023
These include allowing the exceptional supply of certain medicines that may not be authorised in a particular Member State or granting full or partial exemptions to certain labelling and packaging requirements to address severe problems in respect of the availability of some medicines.”
Expert insights. Personalized for you.
98 
Let's personalize your content